Abstract : BGI Genomics Co., Ltd., China's genomics giant, reported surging profits in the first half (H1) of 2020 due to strong demand for its COVID-19 test kits.
SHENZHEN, Aug. 27 (Xinhua) — BGI Genomics Co., Ltd., China’s
genomics giant, reported surging profits in the first half (H1) of 2020
due to strong demand for its COVID-19 test kits.
Its net profit edged up 734.2 percent year on year to 1.65 billion
yuan (about 240 million U.S. dollars) in the January-June period, BGI
Genomics said in its interim financial report filed with the Shenzhen
Stock Exchange.
During the period, the company said it earned revenue of 4.11 billion yuan, a year-on-year increase of 218.1 percent.
In the first six months of 2020, the gene sequencing firm in Shenzhen
spent 169.96 million yuan on research and development, up 11.7 percent
year on year.
Driven by strong business growth, shares of BGI Genomics soared 4.59
percent to close at 145.72 yuan Thursday in Shenzhen. Enditem
About Xinhua Silk Road
Xinhua Silk Road (en.imsilkroad.com) is the Belt and Road Initiative (BRI) portal.China’s silk road economic belt and the 21st century maritime silk road website,includes BRI Policy,BRI Trade,BRI Investment,Belt and Road weekly,Know Belt and Road,and the integrated information services for the Belt and Road Initiative (BRI).
Source: Chinese genomics company BGI reports surging profit in H1
Comments
Post a Comment